The Lemon Fool

Quarterly dividends

The Board has declared a fourth interim dividend for 2023 of 16.00p per share (Q4 2022: 13.75p(3) per share).

Dividends remain an essential component of total shareholder return and GSK recognises the importance of dividends to shareholders. On 23 June 2021, at the GSK Investor Update, GSK set out that from 2022 a progressive dividend policy will be implemented guided by a 40 to 60 percent pay-out ratio through the investment cycle. Consistent with this, and reflecting strong business performance during the year, GSK now expects to declare an increased dividend of 16.00p for Q4 2023 and 58.00p per share for full year 2023. The expected dividend for 2024 is 60.00p. In setting its dividend policy, GSK considers the capital allocation priorities of the Group and its investment strategy for growth alongside the sustainability of the dividend.

Payment of dividends

The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 9 April 2024. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary. The ex-dividend date will be 22 February 2024, with a record date of 23 February 2024 and a payment date of 11 April 2024.

idpickering wrote:Including this;

Quarterly dividends

The Board has declared a fourth interim dividend for 2023 of 16.00p per share (Q4 2022: 13.75p(3) per share).

Dividends remain an essential component of total shareholder return and GSK recognises the importance of dividends to shareholders. On 23 June 2021, at the GSK Investor Update, GSK set out that from 2022 a progressive dividend policy will be implemented guided by a 40 to 60 percent pay-out ratio through the investment cycle. Consistent with this, and reflecting strong business performance during the year, GSK now expects to declare an increased dividend of 16.00p for Q4 2023 and 58.00p per share for full year 2023. The expected dividend for 2024 is 60.00p. In setting its dividend policy, GSK considers the capital allocation priorities of the Group and its investment strategy for growth alongside the sustainability of the dividend.

Payment of dividends

The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 9 April 2024. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary. The ex-dividend date will be 22 February 2024, with a record date of 23 February 2024 and a payment date of 11 April 2024.

https://www.investegate.co.uk/announcem ... ts/8013825

Also posted on Company News here; viewtopic.php?p=643830#p643830

Although I don't hold these any more, I know some hereabouts do, so this may be of interest here.

Ian.

funduffer wrote:
Haleon (HLN), the GSK spin-off, on the other hand looks like a waste of time from the HYP point of view, so I will be looking to offload this soon and re-invest in something better.

FD

monabri wrote:

funduffer wrote:
Haleon (HLN), the GSK spin-off, on the other hand looks like a waste of time from the HYP point of view, so I will be looking to offload this soon and re-invest in something better.

FD

With regard to Haleon, someone might decide to offer £50bn for it..you never know.. Seriously , that is the only reason I'd hold onto it..a vain hope it will be taken over..I think it's a low probability though!


GSK shareholders should have demanded EW resigns ...

funduffer wrote:Thanks for posting, Ian.

It looks like GSK are resuming a progressive dividend policy, although 60p per year only represents a yield of 3.8% based on today's closing price - not really HYP territory. However, I have owned GSK for many years so I welcome the new policy and have no intention of selling.

Haleon (HLN), the GSK spin-off, on the other hand looks like a waste of time from the HYP point of view, so I will be looking to offload this soon and re-invest in something better.

FD

monabri wrote:

funduffer wrote:
Haleon (HLN), the GSK spin-off, on the other hand looks like a waste of time from the HYP point of view, so I will be looking to offload this soon and re-invest in something better.

FD

With regard to Haleon, someone might decide to offer £50bn for it..you never know.. Seriously , that is the only reason I'd hold onto it..a vain hope it will be taken over..I think it's a low probability though!


GSK shareholders should have demanded EW resigns ...

GSK plc today confirmed it has reached a confidential settlement with David Browne, resolving the case he filed in California state court. This case was set to go to trial on 20 February 2024, and instead will now be dismissed. The settlement reflects the Company's desire to avoid the distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.